Dow Down0.32% Nasdaq Down0.62%

Insmed Incorporated (INSM)

12.15 Down 0.31(2.49%) Apr 29, 4:00PM EDT
|After Hours : 12.15 0.00 (0.00%) Apr 29, 4:55PM EDT
ProfileGet Profile for:
Insmed Incorporated
10 Finderne Avenue
Building 10
Bridgewater, NJ 08807
United States - Map
Phone: 908-977-9900

Index Membership:N/A
Full Time Employees:125

Business Summary 

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapies for patients with serious lung diseases. The company’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for patients with nontuberculous mycobacteria lung disease. It is also developing INS1009, a nebulized treprostinil prodrug that is in Phase I study for pulmonary arterial hypertension, idiopathic pulmonary fibrosis, sarcoidosis, and severe refractory asthma. Insmed Incorporated was founded in 1999 and is headquartered in Bridgewater, New Jersey.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Insmed Incorporated

Corporate Governance 
Insmed Incorporated’s ISS Governance QuickScore as of Apr 1, 2016 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 10; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. William H. Lewis , 47
Chief Exec. Officer, Pres and Director
Mr. Andrew T. Drechsler , 44
Chief Financial Officer
Dr. Eugene J. Sullivan M.D., FCCP, 51
Chief Medical & Scientific Officer
Ms. Christine A. Pellizzari , 48
Gen. Counsel and Corp. Sec.
Ms. S. Nicole Schaeffer , 48
Sr. VP of HR & Corp. Services
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders